Discrepancies have been reported between results obtained with tuberculin skin tests (TSTs) performed with use of different reagents. We compared TST results and determined the sensitivities of the two commercially available TSTs in 51 human immunodeficiency virus -negative persons with culture-confirmed active tuberculosis. Simultaneous TSTs were done with use of the Mantoux method and 5 -tuberculin unit purified protein derivative (PPD) tuberculin preparations from single lots of Aplisol and Tubersol. Aplisol skin test reactions ranged from 5 mm to 26 mm (median, 16.0 mm), and Tubersol reactions ranged from 7 mm to 23 mm (median, 15.0 mm). The mean difference in paired reaction sizes for the two reagents was 0.58 mm and was not statistically different from zero (P value, 0.26). The difference in reaction sizes was £2 mm in 55% and §5 mm in 18% of patients. With a cutoff of either 5 mm or 10 mm to define a positive reaction, all results were concordant, with sensitivity of 100% and 96%, respectively. We found indistinguishable reaction size distributions and median TST results for the two commercially available PPD TST reagents, Aplisol and Tubersol, in a population with recent culture-proven tuberculosis. and PPD-standard (PPD-S) [11]. In that same year, production from tuberculin skin testing may lead to unnecessary evaluation and distribution of Aplisol from the old master batch of tuberand treatment of uninfected persons and unwarranted epidemioculin was stopped and a new master batch was prepared [11]. logical investigations. However, the specificity of the TST varBecause the sensitivity of tuberculin testing with these reagents ies according to the prevalence of exposure to nontuberculous has not been compared recently, we compared the reaction distributions of single lots of the two commercially available mycobacteria [3] , and reports of unexpected or falsely positive PPD TST reagents in the United States, Aplisol and Tubersol, TST results as well as discrepancies between results obtained when simultaneously administered to persons with previously with available TST reagents raise important questions about culture-proven tuberculosis. the standardization and performance characteristics of the two PPD reagents commercially available in the United States, Aplisol (Parke-Davis, Morris Plains, NJ) and Tubersol (ConMethods naught, Swiftwater, PA) [4 -9].
It is estimated that 10 -15 million persons in the United
See editorial response by Sbarbaro and Iseman on pages 644-5. States are infected with Mycobacterium tuberculosis [1] . Accurate detection of infection, especially in persons at highest risk
The findings of a 1982 investigation comparing two lots of for progression to clinical disease, is necessary for prevention Aplisol and a single lot of Tubersol suggested that false-posiof disease. The tuberculin skin test (TST) employing intradertive TST results were associated with a single lot of Aplisol mal injection of 5 TU of PPD tuberculin (Mantoux test) is [10] . Also in 1982, a multicenter study found significantly currently the preferred technique for detecting asymptomatic, greater mean reaction sizes with Aplisol than with Tubersol latent M. tuberculosis infection [2] . Falsely positive results and PPD-standard (PPD-S) [11] . In that same year, production from tuberculin skin testing may lead to unnecessary evaluation and distribution of Aplisol from the old master batch of tuberand treatment of uninfected persons and unwarranted epidemioculin was stopped and a new master batch was prepared [11] . logical investigations. However, the specificity of the TST varBecause the sensitivity of tuberculin testing with these reagents ies according to the prevalence of exposure to nontuberculous has not been compared recently, we compared the reaction distributions of single lots of the two commercially available mycobacteria [3] , and reports of unexpected or falsely positive PPD TST reagents in the United States, Aplisol and Tubersol, TST results as well as discrepancies between results obtained when simultaneously administered to persons with previously with available TST reagents raise important questions about culture-proven tuberculosis. the standardization and performance characteristics of the two PPD reagents commercially available in the United States, Aplisol (Parke-Davis, Morris Plains, NJ) and Tubersol (ConMethods naught, Swiftwater, PA) [4 -9] .
Persons aged 18 years and older were recruited from the Seattle -King County (Washington) Department of Public Health Tuberculosis Clinic. Eligibility criteria were (1) either the occurrence within the past 5 years of culture-confirmed Received 16 December 1996; revised 13 March 1997. tuberculosis that resolved with treatment or else current cultureThis research was conducted in accordance with the guidelines of the Human confirmed tuberculosis for which at least 2 months of antituberSubjects Division, University of Washington. Informed consent was obtained culosis therapy had been received and had reduced the signs from all study subjects.
Correspondence: Dr. J. S. Duchin, Seattle -King County Department of Puband symptoms of disease; (2) A sample-size calculation showed that for detection of a skin tests were read at 48 hours for 45 patients (88%) and at 72 hours for six (12%). mean difference in reaction size of §2 mm, with alpha Å 0.05 and beta Å 0.85 (power Å 85%), the required sample size was
The reaction-size distributions for the two reagents are depicted in figure 1 . Aplisol skin test reactions ranged from 5 mm 34 paired results, achieved with 17 subjects undergoing two tests each.
to 26 mm (mean, 15.6 mm; median, 16.0 mm), and Tubersol reactions ranged from 7 mm to 23 mm (mean, 15.0 mm; meThe study protocol was approved by the Human Subjects Review Committee of the University of Washington and the dian, 15.0 mm). There were no significant differences in the mean reaction size by age, race, gender, site of disease, or Centers for Disease Control and Prevention. After informed consent was given, subjects underwent simultaneous TSTs ustime from diagnosis of tuberculosis. The paired differences in Aplisol minus Tubersol reaction sizes for each subject are ing the Mantoux method and 5-TU PPD tuberculin preparations from single lots of Aplisol (lot number 02804P) and Tubersol depicted in figure 2 . The mean difference in paired reaction sizes for the two reagents was 0.58 mm (range, 0 -11 mm) and (lot number 2403-11) provided by the manufacturers. The tests were administered and read in a double-blind design.
was not statistically different from zero (P value, 0.26). The difference in reaction sizes was £2 mm in 55% and §5 mm Prior to placement of the TST, each reagent was randomly assigned to the subject's volar surface of the right or left arm in 18% of patients. With a cutoff of either 5 mm or 10 mm to define a positive reaction, all results were concordant. No suband loaded into coded tuberculin syringes labeled only ''right'' or ''left'' by an investigator not performing the skin testing.
ject experienced blistering related to tuberculin skin testing. Skin testing was performed by a single nurse experienced in placing tuberculin skin tests and measuring the reactions. SubDiscussion jects returned in 48 -72 hours, and results of each test were recorded in millimeters of induration; any adverse events also Several recent reports highlight the uncertainty surrounding were recorded. The reagent code was broken upon completion the interpretion of TST results in clinical situations, especially of the study.
when positive results are unexpected. Lifson et al. [6] reported Clinical information was collected through medical record that among 42 intravenous drug users undergoing TST screenreviews with use of standardized abstraction forms and ining and with an initial reaction to Aplisol of §5 mm, 11 (26%) cluded demographic data, organ site of tuberculosis disease, had no reaction upon retesting with Tubersol (5 of 9 HIVdate and source of specimen positive for M. tuberculosis, hispositive and 6 of 33 HIV-negative persons). Rupp et al. [4] tory of antituberculosis treatment, current medications, and reported that among 26 employees found to have a positive medical conditions known to decrease reactivity to tuberculin.
TST after initial screening with Aplisol, only four had a positive The mean difference in induration for the reagents was comresult when retested with Tubersol. Cieslak et al.
[5] reported pared with the Student's paired t-test and a two-tailed signifia cluster of false-positive TST conversions in 11 pediatric pacance level of 5%. We chose 5-mm and 10-mm cutoffs to tients initially tested with Sclavo (Sclavo, Wayne, NJ) who calculate sensitivity because these values are currently recomretested negative with Aplisol (all Sclavo lots were subsemended for determining TST positivity in populations at inquently recalled by the manufacturer). creased risk for tuberculosis infection [2] .
Results
Fifty-one persons with active tuberculosis diagnosed between December 1992 and March 1995 were enrolled in the study. The median age was 41 years (range, 21 -85 years); 35 (69%) of the patients were male, 25 (50%) were Asian or Pacific Islanders, 16 (32%) were white, 7 (14%) were black, and 2 (4%) were Native American (race was unspecified for 1 patient). Thirty subjects had immigrated to the United States; 22 (73%) were from Southeast Asia and the Philippines, and 21 (70%) had immigrated within the past 5 years.
M. tuberculosis was cultured from a pulmonary source in 44 (86%) of the cases. The remaining sites yielding positive cultures included bone in two cases and lymph node, peritoneal tissue, CSF, and rectal biopsy specimens in one case each. All subjects tested negative for HIV-1 by ELISA at enrollment, and none was taking immunosuppressive medications or had with false-positive reactions (specificity). Because we evaluated the PPD reagents in persons with recently proven tuberculosis, the results do not allow us to determine the specificity of the tests. Additional studies are needed to evaluate the specificity of TSTs in populations at low risk of tuberculosis infection, specifically health care workers, for whom the consequences of false-positive results are of greatest impact with regard to individuals and the public health.
